1. Home
  2. VMD vs CBIO Comparison

VMD vs CBIO Comparison

Compare VMD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$9.10

Market Cap

465.4M

Sector

N/A

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$20.77

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
CBIO
Founded
2006
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
465.4M
537.5M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
VMD
CBIO
Price
$9.10
$20.77
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
413.2K
202.1K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
32.14
N/A
EPS
0.13
N/A
Revenue
$270,280,000.00
$18,500.00
Revenue This Year
$17.88
N/A
Revenue Next Year
$14.98
$279.20
P/E Ratio
$69.15
N/A
Revenue Growth
20.52
N/A
52 Week Low
$6.05
$8.72
52 Week High
$12.61
$27.41

Technical Indicators

Market Signals
Indicator
VMD
CBIO
Relative Strength Index (RSI) 37.89 68.70
Support Level $8.49 $16.77
Resistance Level $10.05 $21.14
Average True Range (ATR) 0.28 1.32
MACD 0.07 0.32
Stochastic Oscillator 54.55 80.79

Price Performance

Historical Comparison
VMD
CBIO

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: